Open Orphan PLC Comment regarding press speculation (5092Z)
September 15 2022 - 2:00AM
UK Regulatory
TIDMORPH
RNS Number : 5092Z
Open Orphan PLC
15 September 2022
Open Orphan plc
("Open Orphan" or the "Company")
Press Speculation
Open Orphan plc (AIM: ORPH), a rapidly growing specialist
contract research organisation (CRO) and world leader in testing
infectious and respiratory disease products using human challenge
clinical trials, notes the media report relating to the allegation
of an incident of potential insider dealing in the Company's shares
by an unconnected private individual in 2020.
The Company confirms that it was made aware of this allegation
by, and at their request, is helping the relevant Irish authorities
in respect of this allegation.
The Board of Open Orphan is satisfied that there are no
implications for the Company in the resolution of this allegation
and confirms that no employee, executive, director or anyone
connected with the Company had any involvement whatsoever in this
matter nor are they suspected of any wrongdoing.
For further information please contact:
Open Orphan plc +44 (0) 20 7756 1300
Yamin Khan, Chief Executive Officer
Liberum Capital (Nominated Adviser and Joint Broker) +44 (0) 20 3100 2000
Ben Cryer/ Edward Mansfield/ Phil Walker/ Will King
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash / James Thompson / Richard Chambers
Davy (Euronext Growth Adviser and Joint Broker) +353 (0) 1 679 6363
Anthony Farrell
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780 or openorphan@walbrookpr.com
Stephanie Cuthbert / Phillip Marriage / +44 (0) 7796 794 663 / +44 (0) 7867 984 082 /
Louis Ashe-Jepson +44 (0) 7747 515 393
Notes to Editors
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing
contract research company that is a world leader in testing
infectious and respiratory disease products using human challenge
clinical trials. The Company provides services to Big Pharma,
biotech, and government/public health organisations.
The Company has a leading portfolio of human challenge study
models for infectious and respiratory diseases, including the
recently established COVID-19 model, and is developing a number of
new models, such as Malaria, to address the dramatic growth of the
global infectious disease market. The Paris and Breda offices have
over 25 years of experience providing drug development services
such as biometry, data management, statistics CMC, PK and medical
writing to third party clients as well as supporting the
London-based challenge studies.
hVIVO runs challenge studies in London from its Whitechapel
quarantine clinic, its state-of-the-art QMB clinic with its highly
specialised on-site virology and immunology laboratory, and its
newly opened clinic in Plumbers Row. To recruit volunteers /
patients for its studies, the Company leverages its unique clinical
trial recruitment capacity via its FluCamp volunteer screening
facilities in London and Manchester. The newly opened facilities
have expanded the scope of the business to enable the offering of
Phase I and Phase II vaccine field trials, PK studies, bridging
studies, and patient trials as part of large international
multi-centre studies.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
SPCUSRBRUVUKAAR
(END) Dow Jones Newswires
September 15, 2022 02:00 ET (06:00 GMT)
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jul 2023 to Jul 2024